
pharma
Advanced CMC Masterclass - EU edition
09-10 November, 2026
A structured approach to drug substance, drugproduct, and analytical development, including lifecycle management
09-10 November, 2026, Virtual
Time Zone: UTC/GMT+1 /CET
Key learnings
Life-cycle
DS & DP
QbD principles
Control
Trusted by over 17,000 delegates across leading companies












Overview
This advanced training course covers the key CMC aspects in the development of drug substances and medicinal products, including analytical development and the product life cycle management with regard to manufacturing processes and analytical procedures. It begins with an introduction to the regulatory documents - specifically the ICH guidelines - that outline the requirements for the proper development of drug substances and drug products and specify the technical information that have to be submitted to the regulatory authorities as part of marketing authorization applications (MAAs, NDAs, etc.).
Based on the quality-by design principles and utilizing quality risk assessment, the training explains the various stages of drug substance / drug product development - such as the selection of starting materials / excipients, the linking of critical process parameters (CPPs) to critical quality attributes (CQAs), and the establishment of the control strategy (including setting of specifications for starting materials / excipients and finished drug substances / drug products). In addition to the process development of active ingredients and medicinal products, the training course covers key aspects of analytical development for drug substances and drug products including the development and validation of analytical procedures. Furthermore, the course provides insight into the selection of primary packaging materials (container closure system) and stability testing to establish the storage conditions and shelf life for the drug substances and drug products.
In addition to these topics, the training course covers clinical phase-dependent approaches used in pharmaceutical and analytical development, as well as post-approval changes within the scope of product life cycle management - such as transfer of analytical procedures.
#masterclass #glceurope #pharma #globalleadingconferences #advancedCMC #cmc #chemical #manufacturing #control
Meet the expert
Trainer

Manfred Fischer
GENERAL MANAGERMANFRED FISCHER CONSULTING
medicinal products.
He started his career in the pharmaceutical industry at AstraZeneca with a leadership role in analytical development. As the next steps in his professional journey, he served in several managerial and leadership roles in analytical development and quality control at AstraZeneca, AltanaPharma, and Eli Lilly. In 2007 Manfred Fischer joined Skyepharma (later acquired by Vectura), Switzerland as head of analytical development. In 2017 he became VP of pharmaceutical development of inhalation
drug products at Vectura. He is the founder and General Manager of Manfred Fischer Consulting, a pharmaceutical company focusing on analytical, formulation and device development consulting.
Reasons to attend a masterclass
Practical knowledge
Interactivity
World-class trainers
Networking
WHO SHOULD ATTEND
-Process analytical chemists and process development scientists
-Process engineers
-Analytical development scientists
-Analytical method and validation experts
-Quality control and quality assurance specialists
-Regulatory affairs CMC managers
-Regulatory affairs CMC authors and reviewers
-Project managers with CMC responsibilities
Ticket options for you
Full eventpass
Learn moreLooking for an in-house training?
Years of experience
Events organized
Speakers
Attendees
Take the next step

